Tae Nyun Kim
Overview
Explore the profile of Tae Nyun Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
1202
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hong J, Kim M, Min K, Won J, Kim T, Lee B, et al.
Diabetes Obes Metab
. 2024 Oct;
27(1):81-91.
PMID: 39375869
Aims: To evaluate the efficacy and safety of add-on dapagliflozin in patients with type 2 diabetes mellitus (T2D) who had inadequate glycaemic control with metformin and linagliptin. Materials And Methods:...
2.
Kim N, Lee J, Chon S, Yu J, Jeong I, Lim S, et al.
Endocrinol Metab (Seoul)
. 2024 Aug;
39(5):722-731.
PMID: 39174014
Backgruound: Atherogenic dyslipidemia, which is frequently associated with type 2 diabetes (T2D) and insulin resistance, contributes to the development of vascular complications. Statin therapy is the primary approach to dyslipidemia...
3.
Joung K, Kim T, Ku E, Lee S, Yoo W, Park K, et al.
J Diabetes Complications
. 2024 Jul;
38(8):108809.
PMID: 39018898
Aims: The objective of this study was to demonstrate that sustained-release (SR) pregabalin is non-inferior to immediate-release (IR) pregabalin in attenuating diabetic peripheral neuropathic (DPN) pain along with patient satisfaction...
4.
Han K, Hwang Y, Moon S, Cho H, Yoo H, Choi S, et al.
Diabetes Obes Metab
. 2024 Jul;
26(9):3743-3752.
PMID: 38978173
Aim: To evaluate the efficacy and safety of gemigliptin and dapagliflozin dual add-on therapy (GEMI + DAPA) to metformin in type 2 diabetes (T2D) patients who had inadequate glycaemic control...
5.
Lee S, Hong S, Sung J, Kim K, Kim S, Cho J, et al.
Medicine (Baltimore)
. 2023 Nov;
102(47):e36122.
PMID: 38013289
Background: We compared the efficacy and safety of low-intensity atorvastatin and ezetimibe combination therapy with moderate-intensity atorvastatin monotherapy in patients requiring cholesterol-lowering therapy. Methods: At 19 centers in Korea, 290...
6.
Lee J, Lee J, Chung M, Ahn J, Choi H, Hong S, et al.
Korean J Intern Med
. 2023 Aug;
38(5):641-650.
PMID: 37635283
Gout is the most common form of arthritis, with the prevalence increasing worldwide. The present treatment guidelines provide recommendations for the appropriate treatment of acute gout, management during the inter-critical...
7.
Lee J, Lee J, Chung M, Ahn J, Choi H, Hong S, et al.
J Rheum Dis
. 2023 Jul;
30(3):141-150.
PMID: 37476677
Gout is the most common form of arthritis, with the prevalence increasing worldwide. The present treatment guidelines provide recommendations for the appropriate treatment of acute gout, management during the inter-critical...
8.
Kim K, Han K, Kim T, Park C, Park J, Kim S, et al.
Diabetes Metab
. 2023 Mar;
49(4):101440.
PMID: 36906135
Aims: This study evaluated the efficacy and safety of enavogliflozin, a novel sodium-glucose cotransporter 2 inhibitor, versus dapagliflozin in Korean patients with type 2 diabetes mellitus (T2DM) inadequately controlled with...
9.
Ko J, Kim T
J Obes Metab Syndr
. 2022 May;
31(2):123-133.
PMID: 35618657
Type 2 diabetes (T2D) has long been regarded as an incurable and chronic disease according to conventional management methods. Clinical and pathophysiological studies on the natural course of T2D have...
10.
Seo D, Bae J, Zhang D, Song W, Kwak H, Heo J, et al.
BMB Rep
. 2021 Oct;
54(11):575-580.
PMID: 34674798
Cisplatin is widely known as an anti-cancer drug. However, the effects of cisplatin on mitochondrial function and autophagyrelated proteins levels in the skeletal muscle are unclear. The purpose of this...